Clinical trial

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

NCT03313661

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Cabergoline Normalized identity: cabergolineView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Gliclazide Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-10-14

PhasePHASE3

Conditions

Diabetesverified · MONDO: diabetes mellitus

Interventions

CabergolineDRUG · verified · RxNorm: cabergoline

GliclazideDRUG

Sponsors & collaborators

Sherief Abd-Elsalamlead sponsor

Mapped research locations

CairoEgypt1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03313661 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.